Tag Archive for: CRO

Image 960x540

Watch this expert-led session to explore the latest trends and insights in gene therapy, including how to model immunosuppressive regimens, key study-design considerations, and the importance of age categories in nonhuman primate research.

Contract Research Organization Julius Clinical (NL) appointed Bassem Saleh as its new Chief Executive Officer. His predecessor, Martijn Wallert, will become an advisor to the Executive Board.

French ERBC and Menarini Biotech from Italy forge a new strategic alliance to accelerate biopharmaceutical development.

Evotec SE is widening its 2022 R&D collaboration SynaptixBio Ltdi to optimise and identify new antisense oligonucleotides to treat children with H-ABC leukodystrophy, a rare genetic myelin synthesis defect that shows similar symptoms such as multiple sclerosis.

Misfolded protein accumulation and evidence of ISR activationis present in multiple neurological conditions. © BMS and Hetz et al, Nat Rev – Neur 2017

Evotec SE has reached a predefined milestone worth €20m in the CRO’s partnership with Bristol Myers Squibb (BMS).

Evotec headquarters in Hamburg. © Evotec SE

Drug discovery CRO Evotec SE announced has entered into a partnership with Inserm, Lille University Hospital and Inserm Transfert to screen new biomarkers and targets in obesity and metabolic diseases.

© ScouserUK - pixabay.com

London-based AI-driven antibody drug discovery specialist LabGenius Ltd has closed a £35m Series B financing round.

© magicmine - stock.adobe.com

Enterprise Therapeutics Ltd. has raised £26m for the Phase IIa trial of ETD001, a novel cystic fibrosis treatment, with investment led by Panakes Partners and participation from existing investors.

In 2021, Metrion Biosciences moved into its labs in Cambridge, UK. © Metrion Biosciences Ltd

Cambridge-based Metrion Biosciences Ltd has secured £3.5m in new equity financing – led by Maven Capital Partners and a £1m contribution from existing investor, Gresham House Ventures.

© vfa

British drug discovery specialist Sygnature Discovery Ltd has taken over Canadian NuChem Sciences Inc., one of North America’s largest discovery CROs